Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat ...

Vertex的药物suzetrigine被誉为一项科学突破，因为它阻断了一种有助于控制人体神经元活动的钠通道，在不进入大脑的情况下治疗疼痛。这使得它比阿片类药物更不容易上瘾，在截至2024年6月的一年中，阿片类药物导致约7万人因过量服用而死亡。如果获 ...

周四，Evercore ISI重申了对Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)的"优于大市"评级，并坚持515.00美元的目标价。根据 InvestingPro ...

在其他近期新闻中，Vertex Pharmaceuticals ...

苹果公司（AAPL）和Vertex Pharmaceuticals（VRTX）看似没有太多共同之处。前者是一家消费科技领导者，而后者则在生物技术行业运作。然而，它们有一个共同点，那就是能让长期股东感到满意。过去十多年，苹果和Vertex ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity” third ...

Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 2 study of suzetrigine for painful ...

CNBC’s Jim Cramer explains why he is keeping an eye on shares of Vertex Pharmaceuticals. NFL News: Andy Reid and Chiefs ...

BofA lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $522 from $545 and keeps a Buy rating on the shares after the company ...

Vertex Pharmaceuticals (VRTX) is plummeting after disappointing trial results, headed for its worst day in four years ...

RBC Capital analyst Brian Abrahams lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $400 from $451 and keeps a Sector ...